Saturday 19 May 2012
Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment